1Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea
3Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
© Copyright 2023. Korean Association for the Study of Intestinal Diseases.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Funding Source
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HR21 C0198). This work was also supported by the National Research Foundation of Korea (NRF) grant, funded by the Korean government (MSIT), awarded to Park SH (No. 2021R1G1A1094252).
Conflict of Interest
No potential conflict of interest relevant to this article was reported.
Data Availability Statement
All data, analytic methods, and study materials relevant to the study are included in the article or available on request from the corresponding author, Park SH.
Author Contribution
Conceptualization: Lee JL, Kang SB, Park SH. Data curation: Lee JS, Kang SB, Park K, Yoon YS, Yu CS, Hwang SW, Ye BD, Yang SK. Formal analysis: Lee JS, Park SH. Writing - original draft: Lee JS, Park SH. Writing - review & editing: Kang SB, Yoon YS, Yu CS, Hwang SW, Ye BD, Yang SK, Lee JL. Approval of final manuscript: all authors.
Characteristic | Value (n = 26) |
---|---|
Age (yr) | 31.5 (19–62) |
Male sex | 19 (73.1) |
Disease duration (mo) | 120.5 (85–150) |
Symptoms at diagnosis | |
Abdominal pain | 26 (100) |
Weight loss | 8 (30.8) |
Diarrhea | 5 (19.2) |
Vomiting | 3 (11.5) |
Fecal vomiting | 0 |
Previous surgical history | 16 (61.5) |
Right hemi-colectomy | 11 (42.3) |
Ileocecal resection | 2 (7.7) |
SB R&A | 1 (3.8) |
Appendectomy | 2 (7.7) |
Preoperative use of biologics | 14 (53.8) |
Preoperative treatment | |
5-ASA | 6 (23.1) |
Immunomodulators | 1 (3.8) |
Biologics | 3 (11.5) |
5-ASA + immunomodulators | 5 (19.2) |
5-ASA + biologics | 2 (7.7) |
Immunomodulators + biologics | 3 (11.5) |
5-ASA + immunomodulators + biologics | 6 (23.1) |
Postoperative treatmenta | |
5-ASA | 3 (11.5) |
Immunomodulators | 2 (7.7) |
Biologics | 1 (3.8) |
5-ASA + immunomodulators | 7 (26.9) |
5-ASA + biologics | 4 (15.4) |
Immunomodulators + biologics | 2 (7.7) |
5-ASA + Immunomodulators + biologics | 6 (23.1) |
Laboratory finding at inclusion | |
Hemoglobin (g/dL) | 11.9 (9.3–12.8) |
White blood cell (/µL) | 7,250 (4,600–10,300) |
Erythrocyte sedimentation rate (mm/hr) | 23.0 (7.5–56.5) |
C-reactive protein (mg/dL) | 2.44 (0.85–4.40) |
Albumin (g/dL) | 2.55 (1.80–3.30) |
ASCA positiveb | 19 (86.4) |
Smoking at diagnosis | |
Never smoker | 18 (69.2) |
Current smoker | 8 (30.8) |
CD: disease behavior at diagnosis | |
Inflammatory (B1) | 10 (38.5) |
Stricturing (B2) | 4 (15.4) |
Penetrating (B3) | 12 (46.2) |
Perianal (p) | 6 (23.1) |
CD: disease location at diagnosis | |
Ileum (L1) | 3 (11.5) |
Colon (L2) | 3 (11.5) |
Ileocolon (L3) | 20 (76.9) |
Upper gastrointestinal modifier (L4) | 5 (19.2) |
Fistula origin | |
Ileocolic anastomosis | 12 (46.2) |
Ascending colon | 9 (34.6) |
Transverse colon | 3 (11.5) |
Small bowel | 2 (7.7) |
Diagnostic toolc | |
Esophagogastroduodenoscopy | 8 (30.8) |
Upper gastrointestinal series | 1 (3.8) |
Computed tomography | 12 (46.2) |
Intraoperatively | 13 (50.0) |
Surgical method | |
Primary duodenal repair | 23 (88.5) |
Duodenal wedge resection | 2 (7.7) |
Duodenal glue treatment | 1 (3.8) |
Values are presented as median (range) or number (%).
a One patient expired because of peritonitis caused by uncontrolled enteric and colo-duodenal fistula.
b Three patients were not measured.
c Eight patients were diagnosed using more than 2 techniques.
SB R&A, small bowel resection and anastomosis; 5-ASA, 5-aminosalicylic acid; ASCA, anti-Saccharomyces cerevisiae antibody; CD, Crohn’s disease
Characteristic | Value (n = 26) |
---|---|
Age (yr) | 31.5 (19–62) |
Male sex | 19 (73.1) |
Disease duration (mo) | 120.5 (85–150) |
Symptoms at diagnosis | |
Abdominal pain | 26 (100) |
Weight loss | 8 (30.8) |
Diarrhea | 5 (19.2) |
Vomiting | 3 (11.5) |
Fecal vomiting | 0 |
Previous surgical history | 16 (61.5) |
Right hemi-colectomy | 11 (42.3) |
Ileocecal resection | 2 (7.7) |
SB R&A | 1 (3.8) |
Appendectomy | 2 (7.7) |
Preoperative use of biologics | 14 (53.8) |
Preoperative treatment | |
5-ASA | 6 (23.1) |
Immunomodulators | 1 (3.8) |
Biologics | 3 (11.5) |
5-ASA + immunomodulators | 5 (19.2) |
5-ASA + biologics | 2 (7.7) |
Immunomodulators + biologics | 3 (11.5) |
5-ASA + immunomodulators + biologics | 6 (23.1) |
Postoperative treatment |
|
5-ASA | 3 (11.5) |
Immunomodulators | 2 (7.7) |
Biologics | 1 (3.8) |
5-ASA + immunomodulators | 7 (26.9) |
5-ASA + biologics | 4 (15.4) |
Immunomodulators + biologics | 2 (7.7) |
5-ASA + Immunomodulators + biologics | 6 (23.1) |
Laboratory finding at inclusion | |
Hemoglobin (g/dL) | 11.9 (9.3–12.8) |
White blood cell (/µL) | 7,250 (4,600–10,300) |
Erythrocyte sedimentation rate (mm/hr) | 23.0 (7.5–56.5) |
C-reactive protein (mg/dL) | 2.44 (0.85–4.40) |
Albumin (g/dL) | 2.55 (1.80–3.30) |
ASCA positive |
19 (86.4) |
Smoking at diagnosis | |
Never smoker | 18 (69.2) |
Current smoker | 8 (30.8) |
CD: disease behavior at diagnosis | |
Inflammatory (B1) | 10 (38.5) |
Stricturing (B2) | 4 (15.4) |
Penetrating (B3) | 12 (46.2) |
Perianal (p) | 6 (23.1) |
CD: disease location at diagnosis | |
Ileum (L1) | 3 (11.5) |
Colon (L2) | 3 (11.5) |
Ileocolon (L3) | 20 (76.9) |
Upper gastrointestinal modifier (L4) | 5 (19.2) |
Fistula origin | |
Ileocolic anastomosis | 12 (46.2) |
Ascending colon | 9 (34.6) |
Transverse colon | 3 (11.5) |
Small bowel | 2 (7.7) |
Diagnostic tool |
|
Esophagogastroduodenoscopy | 8 (30.8) |
Upper gastrointestinal series | 1 (3.8) |
Computed tomography | 12 (46.2) |
Intraoperatively | 13 (50.0) |
Surgical method | |
Primary duodenal repair | 23 (88.5) |
Duodenal wedge resection | 2 (7.7) |
Duodenal glue treatment | 1 (3.8) |
Values are presented as median (range) or number (%). One patient expired because of peritonitis caused by uncontrolled enteric and colo-duodenal fistula. Three patients were not measured. Eight patients were diagnosed using more than 2 techniques. SB R&A, small bowel resection and anastomosis; 5-ASA, 5-aminosalicylic acid; ASCA, anti-